Skip to main content

Table 1 Patient characteristics from study 1 and 2

From: Patient-reported outcomes item selection for bladder cancer patients in chemo- or immunotherapy

Clinical data Total
n = 79 (%)
Study 1
N = 30 (%)
Study 2
n = 49 (%)
Gender  Men 64 (81%) 22 (73%) 42 (86%)
   Women 15 (19%) 8 (27%) 7 (14%)
Median age, yrs. (range) 68 (35–82) 68 (35–82) 68 (48–80)
Stage  Locally advanced 26 (33%) 13 (43%) 13 (27%)
   Metastatic 53 (67%) 17 (57%) 36 (73%)
Treatmenta  Cisplatin + gemcitabine 46 (59%) 22 (76%) 24 (49%)
   Carboplatin + gemcitabine 9 (11%) 6 (21%) 3 (6%)
   Vinflunine 3 (4%) 1 (3%) 2 (4%)
   Pembrolizumab 20 (26%) 0 (0%) 20 (41%)
Admission to hospital  No 32 (41%) 10 (34%) 22 (45%)
   Yes 46 (59%) 19 (66%) 27 (55%)
  1. aOne patient in study 1 never started treatment due to cerebral stroke before initiation of treatment
\